Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis.

IF 2 4区医学 Q3 CLINICAL NEUROLOGY

Acta neurologica Belgica Pub Date : 2024-12-30 DOI:10.1007/s13760-024-02709-4

Ocílio Ribeiro Gonçalves, Arquimedes Barros Nascimento, Victor Gonçalves Soares, David Abraham, Gabriel de Almeida Monteiro, João Luís Reis Freitas, Jonatas Paulino da Cunha Monteiro Ribeiro, Bianca Leal Ribeiro, João Victor Araújo de Oliveira, Marco Antonnio Rocha Dos Santos, João Paulo Mota Telles, Flávio Sekeff-Sallem, Kelson James Almeida

{"title":"Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis.","authors":"Ocílio Ribeiro Gonçalves, Arquimedes Barros Nascimento, Victor Gonçalves Soares, David Abraham, Gabriel de Almeida Monteiro, João Luís Reis Freitas, Jonatas Paulino da Cunha Monteiro Ribeiro, Bianca Leal Ribeiro, João Victor Araújo de Oliveira, Marco Antonnio Rocha Dos Santos, João Paulo Mota Telles, Flávio Sekeff-Sallem, Kelson James Almeida","doi":"10.1007/s13760-024-02709-4","DOIUrl":null,"url":null,"abstract":"Background: Recent evidence indicates that statins have anti-inflammatory and antioxidant effects, leading to several investigations of whether statins have a neuroprotective effect and may benefit patients with Parkinson's disease (PD). However, the potential mechanisms of this class of medications as modifiers of the course of PD in already diagnosed patients is still unclear.Objectives: To assess the effectiveness of statins as modifiers of established PD.Methods: Two investigators systematically searched for randomized clinical trials and observational studies comparing PD patients treated with statins versus those treated without statins. The search was conducted in PubMed, Embase, Cochrane, and Web of Science. The outcome of interest was the change in the MDS-UPDRS III (Movement Disorder society-Unified Parkinson's Disease Rating Scale Part III) and UPDRS III scores from baseline. Statistical analysis was performed using R Studio 4.3.2.Results: Four studies, totaling 472 patients, were included. The standardized mean difference for the MDS-UPDRS Part III and UPDRS Part III scales between statin and non-statin groups was - 0.13 (95% CI - 0.44 to 0.17; p = 0.39; I2 = 58%), and there was no statistical significant difference regarding this outcome.Conclusion: There was no statistical significance for the potential clinical benefit of statins as modifiers of the disease course in PD patients.","PeriodicalId":7042,"journal":{"name":"Acta neurologica Belgica","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13760-024-02709-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recent evidence indicates that statins have anti-inflammatory and antioxidant effects, leading to several investigations of whether statins have a neuroprotective effect and may benefit patients with Parkinson's disease (PD). However, the potential mechanisms of this class of medications as modifiers of the course of PD in already diagnosed patients is still unclear.

Objectives: To assess the effectiveness of statins as modifiers of established PD.

Methods: Two investigators systematically searched for randomized clinical trials and observational studies comparing PD patients treated with statins versus those treated without statins. The search was conducted in PubMed, Embase, Cochrane, and Web of Science. The outcome of interest was the change in the MDS-UPDRS III (Movement Disorder society-Unified Parkinson's Disease Rating Scale Part III) and UPDRS III scores from baseline. Statistical analysis was performed using R Studio 4.3.2.

Results: Four studies, totaling 472 patients, were included. The standardized mean difference for the MDS-UPDRS Part III and UPDRS Part III scales between statin and non-statin groups was - 0.13 (95% CI - 0.44 to 0.17; p = 0.39; I² = 58%), and there was no statistical significant difference regarding this outcome.

Conclusion: There was no statistical significance for the potential clinical benefit of statins as modifiers of the disease course in PD patients.

查看原文本刊更多论文

他汀类药物作为帕金森病的潜在疾病改善疗法：系统回顾和荟萃分析与试验序列分析。

背景：最近的证据表明他汀类药物具有抗炎和抗氧化作用，这导致了一些关于他汀类药物是否具有神经保护作用并可能有益于帕金森病（PD）患者的研究。然而，这类药物在已经诊断的PD患者中作为PD病程调节剂的潜在机制尚不清楚。目的：评价他汀类药物作为既定PD调节剂的有效性。方法：两名研究者系统地检索了随机临床试验和观察性研究，比较了接受他汀类药物治疗和未接受他汀类药物治疗的PD患者。检索在PubMed， Embase， Cochrane和Web of Science中进行。感兴趣的结果是MDS-UPDRS III（运动障碍协会统一帕金森病评定量表第三部分）和UPDRS III评分从基线的变化。采用R Studio 4.3.2进行统计分析。结果：纳入4项研究，共472例患者。他汀类药物组和非他汀类药物组MDS-UPDRS第三部分和UPDRS第三部分量表的标准化平均差异为- 0.13 (95% CI - 0.44至0.17；p = 0.39；I2 = 58%)，该结果无统计学差异。结论：他汀类药物作为PD患者病程调节剂的潜在临床获益无统计学意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta neurologica Belgica 医学-临床神经学

CiteScore

4.20

自引率

3.70%

发文量

300

审稿时长

6-12 weeks

期刊介绍： Peer-reviewed and published quarterly, Acta Neurologica Belgicapresents original articles in the clinical and basic neurosciences, and also reports the proceedings and the abstracts of the scientific meetings of the different partner societies. The contents include commentaries, editorials, review articles, case reports, neuro-images of interest, book reviews and letters to the editor. Acta Neurologica Belgica is the official journal of the following national societies: Belgian Neurological Society Belgian Society for Neuroscience Belgian Society of Clinical Neurophysiology Belgian Pediatric Neurology Society Belgian Study Group of Multiple Sclerosis Belgian Stroke Council Belgian Headache Society Belgian Study Group of Neuropathology